SCHEMBL4489143

SCHEMBL4489143

O=S(=O)(NCc1cc(-c2ccc(Cl)cc2)c(-c2ccc(Cl)cc2Cl)s1)c1ccc(F)c(Cl)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT1 P17948 1/20 0.42
FLT4 P35916 1/20 0.42
KDR P35968 1/20 0.42
GRIN2A Q12879 3/20 0.42
GRIN1 Q05586 2/20 0.42
GRIN2B Q13224 1/20 0.41
MAPT P10636 2/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
HTT P42858 1/20 0.39
HSD11B1 P28845 1/20 0.39
PTGS2 P35354 6/20 0.38
PTGS1 P23219 3/20 0.38
IDH2 P48735 2/20 0.38
CYP19A1 P11511 1/20 0.38
NPC1 O15118 1/20 0.37
ALDH1A1 P00352 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4480639 0.91 MAPT (0.42) FLT1FLT4KDRMAPTCYP1A2
SCHEMBL4496371 0.88 EEF2K (0.39) MAPTCYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL4494108 0.88 ALDH1A1 (0.43) MAPTCYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL4490242 0.87 ALDH1A1 (0.42) FLT1FLT4KDRMAPTCYP1A2
SCHEMBL4500127 0.86 CYP19A1 (0.44) FLT1FLT4KDRMAPTCYP1A2
SCHEMBL4490058 0.84 MALT1 (0.41) MAPTHTT
SCHEMBL4492694 0.84 MAPT (0.41) FLT1FLT4KDRGRIN2AGRIN1
SCHEMBL4498936 0.84 FLT1 (0.44) FLT1FLT4KDRMAPTCYP1A2
SCHEMBL4508036 0.83 KDM1A (0.46) MAPTHTTHSD11B1ALDH1A1
SCHEMBL4507950 0.83 NR3C1 (0.46) MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7589120-B2 N-[(4,5-diphenyl-2-thienyl)methyl]sulfonamide derivatives, preparation thereof and their therapeutic application SANOFI-AVENTIS (FR) 2009-09-15 US claimed
US-20070287744-A1 N-[(4,5-DIPHENYL-2-THIENYL)METHYL]SULFONAMIDE DERIVATIVES, PREPARATION THEREOF AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2007-12-13 US claimed
US-7589120-B2 N-[(4,5-diphenyl-2-thienyl)methyl]sulfonamide derivatives, preparation thereof and their therapeutic application SANOFI-AVENTIS (FR) 2009-09-15 US disclosed
US-20070287744-A1 N-[(4,5-DIPHENYL-2-THIENYL)METHYL]SULFONAMIDE DERIVATIVES, PREPARATION THEREOF AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2007-12-13 US disclosed
EP-1841754-A1 N-[(4,5-DIPHENYL-2-THIENYL)METHYL]SULFONAMIDE DERIVATIVES, PREPARATION THEREOF AND THEIR THERAPEUTIC APPLICATION Sanofi-Aventis (FR) 2007-10-10 EP disclosed
WO-2006077320-A1 N-[(4,5-DIPHENYL-2-THIENYL)METHYL]SULFONAMIDE DERIVATIVES, PREPARATION THEREOF AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2006-07-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070287744-A1 N-[(4,5-DIPHENYL-2-THIENYL)METHYL]SULFONAMIDE DERIVATIVES, PREPARATION THEREOF AND THEIR THERAPEUTIC APPLICATION TPMT, TXNRD2, ARG2 FLT1 2173/4885FLT4 1709/4885KDR 2106/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.